

Regd. Office :

'Zydus Tower'
Satellite Cross Roads
Ahmedabad 380 015, India.
Phone : +91-79-2686 8100 (20 lines)
Fax : + 91-79-2686 2363
www.zyduscadila.com
CIN : L24230GJ1995PLC025878

July 8, 2017

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: Press Release

Dear Sir / Madam,

We enclose herewith a copy of press release dated July 8, 2017 titled "Zydus receives Final Approval from the USFDA for Doxazosin Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

for, [Signature]
UPEN H. SHAH
COMPANY SECRETARY

Zydus receives Final Approval from the USFDA for Doxazosin Tablets

Ahmedabad, 8 July 2017

Zydus Cadila has received the final approval from the USFDA to market Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg, and 8 mg.. The drug is a selective alpha blocker used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia.

Zydus Cadila has also received the tentative approval from the USFDA to market Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg. The drug is an atypical anti-psychotic used in the treatment of schizophrenia.

Both Doxazosin Tablets and Lurasidone Hydrochloride Tablets will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
